Somatostatin_octretide for prevention of rebleeding from gastrointestinal angiodysplasias - SOPRANO

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-005313-38-DE

Enrollment

102

Registered

2006-03-03

Start date

2006-07-17

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

study to investigate the efficacy of Octeoid LAR plus standard therapy versus standard therapy alone in patients with bleeding gastrointestinal angiodysplasias

Interventions

Trade Name: Sandostatin Pharmaceutical Form: Solution for injection INN or Proposed INN: Octreotide Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 500- Pharmaceuti

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - patients about 18 - performed ÖGD, colosscopy or video pill - one or more gastrotestinale haemorrage during the last three month - detection of angiodysplasia Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: -Patients with bad general conditions -other reasons for gastrointestinal bleeding (e. g. tumors, erosion, ulzera, varices) -Hypertriglyceridaemie -choledocholithiasis

Design outcomes

Primary

Measure	Time frame
Main Objective: investigate the frequency of recurrent haemorrage in patients with bleeding gastrointestinal angiodysplasis;Secondary Objective: ;Primary end point(s): investigate the frequency of recurrent haemorrage in patients with bleeding gastrointestinal angiodysplasis	—

Countries

Germany

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026